Thursday, August 06, 2009
Biosimilars Next Move .........................
What do you think which therapeutic segment will be the major focus for Bio similar companies over the next 5 years? Earlier in the first part of 2000 the bio similar companies were majorly focused on diabetics segment and now they have diversified into Cancer therapy which includes Monoclonal antibody production.....In coming time we are going to see many players not only from Europe but also from India and China in this segment.......Infact several Indian companies have started producing in pilot scale and some have even launched their products such as Dr Reddy's Rituximab bio similar product.........And in 2 to 3 years these companies might think of launching these MAbs in regulated market.....I hope that Indian Bio similar companies are part of the bigger picture soon :)
Subscribe to:
Post Comments (Atom)
I do agree with you oncology is the next in-thing.. But always tend to make one mistake compare oncology with diabetes and obesity. Oncology deals with so many cancers with differnt risk factors and different pathophysiology... So the next question is which all cancer would the pharmaceuticals target [ I hope i knew the answer , would have in-lincense few of them ;) ]
ReplyDeleteWe will be able to help you out in this matter :)
ReplyDelete